MTEMQ — Molecular Templates Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$9.66m
- $57.31m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -99.14% | ||
| Return on Equity | n/a | ||
| Operating Margin | -74.02% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.27 | 18.84 | 38.7 | 19.75 | 57.31 | 12.33 | 1.26 | 33.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Directors
- Harold Selick CHM (66)
- Jason Kim PRE (46)
- Eric Poma CEO (49)
- Sean McLennan CFO (51)
- Roger Waltzman OTH (53)
- David Hirsch IND (50)
- David Hoffmann IND (76)
- Kevin Lalande IND (48)
- Jonathan Lanfear IND (52)
- Scott Morenstein IND (45)
- Corazon Sanders IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 17th, 2001
- Public Since
- February 4th, 2005
- No. of Employees
- 62
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 6,583,880
- Address
- 9301 Amberglen Blvd, Suite 100, AUSTIN, 78729-1153
- Web
- https://www.mtem.com/
- Phone
- +1 5128961555
- Auditors
- Ernst & Young LLP
Upcoming Events for MTEMQ
Q2 2025 Molecular Templates Inc Earnings Release
Molecular Templates Inc Annual Shareholders Meeting
Similar to MTEMQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Molecular Templates share price?
As of Today at 22:06 UTC, shares in Molecular Templates are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Molecular Templates share price performed this year?
Shares in Molecular Templates last closed at $0.00 and the price had moved by -99.99% over the past 365 days. In terms of relative price strength the Molecular Templates share price has underperformed the S&P500 Index by -99.99% over the past year.
What are the analyst and broker recommendations for Molecular Templates?
The overall consensus recommendation for Molecular Templates is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Molecular Templates dividend yield?
Molecular Templates does not currently pay a dividend.
Does Molecular Templates pay a dividend?
Molecular Templates does not currently pay a dividend.
When does Molecular Templates next pay dividends?
Molecular Templates does not currently pay a dividend.
How do I buy Molecular Templates shares?
To buy shares in Molecular Templates you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Molecular Templates?
As of the previous close price of $0.00, shares in Molecular Templates had a market capitalisation of $0.00m.
Where are Molecular Templates shares listed?
Here are the trading details for Molecular Templates:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MTEMQ
What kind of share is Molecular Templates?
Based on an overall assessment of its quality, value and momentum Molecular Templates is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Molecular Templates share price forecast for 2025?
The analyst consensus target price for shares in Molecular Templates is $18.00. That is 17999900% above the last closing price of $0.00.
Analysts covering Molecular Templates currently have a consensus Earnings Per Share (EPS) forecast of -$2.93 for the next financial year.
Find out moreWhat is the trend in the Molecular Templates share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Molecular Templates. Over the past six months, its share price has underperformed the S&P500 Index by -99.98%.
As of the last closing price of $0.00, shares in Molecular Templates were trading -99.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Molecular Templates PE Ratio?
The Molecular Templates PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Molecular Templates?
Molecular Templates' management team is headed by:
- Harold Selick - CHM
- Jason Kim - PRE
- Eric Poma - CEO
- Sean McLennan - CFO
- Roger Waltzman - OTH
- David Hirsch - IND
- David Hoffmann - IND
- Kevin Lalande - IND
- Jonathan Lanfear - IND
- Scott Morenstein - IND
- Corazon Sanders - IND